Should fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) staging exams vs. no PET staging exams be used for patients with clinical stage 1 breast cancer without symptoms suggestive of metastases?
For breast cancer patients without symptoms suggestive of metastases at clinical stage 1, the ECIBC's Guidelines Development Group (GDG) recommends against using positron emission tomography-computed tomography (PET-CT).
Strong recommendation against the intervention
Very low certainty of the evidence
For triple negative tumours and HER2 positive evidence suggests that there is no additional benefit because of no increased risks from metastases.
The GDG suggests research to clarify the clinical significance of true positives (for all stages).